UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

[x]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014

 

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from N/A to N/A

  

Commission File No. 000-28745

  

Cloud Medical Doctor Software Corporation

 

(Name of small business issuer as specified in its charter)

 

(formerly National Scientific Corporation)

 

Texas	86-0837077
( State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

                                                                                                         

1291 Galleria Drive, Suite 200

Henderson, NV 89014

(Address of principal executive offices) (Zip Code)

 

(702) 818-9011

Registrant’s telephone number, including area code

 

Indicate by check mark whether the Registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days:  Yes [X] No [ ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	[ ]	Accelerated filer	[ ]
Non–Accelerated filer	[ ]	Smaller reporting company	[x]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act). Yes [ ] No [x]

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class		Outstanding at  May 1, 2014
Common stock, $0.01 par value		248,256,722

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION

INDEX TO FORM 10-Q FILING

FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2014 AND 2013

 

TABLE OF CONTENTS

 

				PAGE
PART I - FINANCIAL INFORMATION
Item 1.		Consolidated Financial Statements (Unaudited)			4
		Balance Sheets			5
		Statements of Operations			6
		Statements of Cash Flows			7
		Notes to Consolidated Financial Statements			7
Item 2.		Management Discussion & Analysis of Financial Condition and Results of Operations			26
Item 3		Quantitative and Qualitative Disclosures About Market Risk			30
Item 4.		Controls and Procedures			30

 

PART II - OTHER INFORMATION
Item 1.		Legal Proceedings			31
Item 1A.		Risk Factors			31
Item 2.		Unregistered Sales of Equity Securities and Use of Proceeds			32
Item 3.		Defaults Upon Senior Securities			34
Item 4.		Mining Safety Disclosures			34
Item 5		Other information			34
Item 6.		Exhibits			34
CERTIFICATIONS

 

31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act.
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act.
32.2	Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act.
32.2	Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act.

PART I

FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

The accompanying interim financial statements have been prepared in accordance with the instructions to Form 10-Q.  Therefore, they do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' equity in conformity with generally accepted accounting principles.  Except as disclosed herein, there has been no material change in the information disclosed in the notes to the financial statements included in the Company's Annual Report on Form 10-K for the year ended September 30, 2013.  In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.  Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that can be expected for the year ending September 30, 2014.

 

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
		March 31,				September 30,
		2014				2013
ASSETS
CURRENT ASSETS:
Cash		$	7,656			$	8,587
Accounts receivable			5,176				8,338
Total current assets			12,832				16,925
Software, net			701,611				817,921
TOTAL ASSETS		$	714,443			$	834,846
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES:
Accounts payable and accrued expenses			699,559			$	361,994
Liabilities attributed to discontinued operations			42,873				35,356
Lines of credit			87,041				9,796
Total current liabilities			829,473				407,146
TOTAL LIABILITIES			829,473				407,146
COMMITMENTS AND CONTINGENCIES			—				—
STOCKHOLDERS' EQUITY (DEFICIT):
Preferred stock, $0.01 par value, 4,000,000 shares authorized; 4,000,000 issued and outstanding			40,000				40,000
Common stock, $0.01 par value, 650,000,000 shares authorized; 246,829,216 and 214,624,216 issued and outstanding			2,468,292				2,146,242
Additional paid-in capital			25,214,828				24,783,723
Accumulated deficit			(27,838,150	)			(26,542,265	)
Total stockholders' equity  (deficit)			(115,030	)			427,700
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		$	714,443			$	834,846
The accompanying notes are an integral part of these unaudited financial statements.

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
		Three Months Ended								Six Months Ended
		March 31,								March 31,
		2014				2013				2014				2013
REVENUES		$	105,118			$	174,214			$	222,675			$	323,571
COST OF REVENUES			61,155				61,155				122,310				121,160
GROSS PROFIT			43,963				113,059				100,365				202,411
OPERATING EXPENSES:
Selling, general and administrative			1,106,142				224,454				1,328,218				343,325
Research and development			30,000				55,000				60,000				95,000
Total operating expenses			1,136,142				279,454				1,388,218				438,325
Gain on the disposal of assets			—				1,353				—				1,353
OPERATING LOSS			(1,092,179	)			(165,042	)			(1,287,853	)			(234,561	)
OTHER INCOME (EXPENSE)
Interest expense			(279	)			(69	)			(515	)			(196	)
Total other income expense			(279	)			(69	)			(515	)			(196	)
LOSS FROM CONTINUING OPERATIONS			(1,092,458	)			(165,111	)			(1,288,368	)			(234,757	)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS			3,198				(38	)			(7,517	)			58,946
NET LOSS		$	(1,089,260	)		$	(165,149	)		$	(1,295,885	)		$	(175,811	)
NET LOSS PER COMMON SHARE:
Basic and diluted
Continuing operations		$	(0.00	)		$	(0.00	)		$	(0.01	)		$	(0.00	)
Discontinued operations		$	0.00			$	(0.00	)		$	(0.00	)		$	0.00
Total		$	(0.00	)		$	(0.00	)		$	(0.01	)		$	(0.00	)
WEIGHTED AVERAGE NUMBER COMMON SHARES OUTSTANDING
Basic and diluted			224,546,327				212,756,568				219,656,908				212,472,748
The accompanying notes are an integral part of these unaudited financial statements.

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
		SIX MONTHS ENDED
		March 31,
		2014				2013
Net loss		$	(1,295,885	)		$	(175,811	)
Income from discontinued operations			(7,517	)			58,946
Loss from continuing operations			(1,288,368	)			(234,757	)
Adjustments to reconcile net loss from continuing operations to net cash from operating activities:
Depreciation and amortization			122,310				121,160
Common stock issued for compensation			666,750				28,155
Common stock issued for software sales			5,700				9,350
Gain on the disposal of assets			—				(1,353	)
Changes in operating assets and liabilities:
Accounts receivable			3,162				3,012
Accounts payable and accrued expenses			397,270				88,638
Net cash (used in) provided by operating activities			(93,176	)			14,205
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of assets			—				1,353
Net cash provided by investing activities			—				1,353
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of advances from officer			—				(25,591	)
Proceeds from line of credit			78,245				2,500
Repayment of line of credit			(1,000	)			(22,152	)
Common stock issued for cash			15,000				141,000
Net cash provided by financing activities			92,245				95,757
INCREASE (DECREASE) IN CASH			(931	)			111,315
CASH, BEGINNING OF PERIOD			8,587				51,356
CASH, END OF PERIOD		$	7,656			$	162,671
SUPPLEMENTAL DISCLOSURE
Interest paid		$	—			$	—
Taxes paid		$	—			$	—
NONCASH INVESTING AND FINANCING ACTIVITIES
Write-off of related party debt to additional paid-in capital		$	59,704			$	—
Common stock issued to purchase software		$	6,000			$	13,000
Accrual of software acquisition costs		$	—			$	23,000
The accompanying notes are an integral part of these unaudited financial statements.

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION

NOTES TO FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2014 AND 2013

(Unaudited)

 

NOTE 1- DESCRIPTION OF BUSINESS

 

Cloud Medical Doctor Software Corporation (the “Company”) was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation. 

 

In the year ended September 30, 2011, Cloud-MD introduced the Cloud-MD Office, a “Cloud Based”, 5010 ready and ICD-10 compliant, fully integrated and interoperable suite of medical software and services, designed by experienced healthcare analysts and programmers for healthcare providers, that produces “Actionable Information” to help Independent Physician Practices, New Care Delivery Models (ACO), Healthcare Systems and Billing Services optimize a wide range of business processes resulting in Increased Profits, Higher Quality, Greater Efficiency, Noticeable Cost Reductions and Better Patient Care. Current software product offerings include Practice Management, Electronic Medical Records, Revenue Management, Patient Financial Solutions, Medical and Pharmaceutical Supply Management, Claims Management and PHI Exchange.

 

In the year ended September 30, 2012, Cloud-MD launched Cloud-MD Billing Services which provides management of medical claims from posting physician charges and payments into our medical billing software. The software uses a continuous insurance claim follow-up system to track and research all rejected or denied medical claims; a Comprehensive Reporting module that includes monthly financial statements sent to our clients so they can see how their practice is performing and a variety of detailed reports giving our clients the necessary information and tools used to assist in the increased production which leads to more profit; and patient account inquiries and support to assist patients with their billing and insurance questions.

 

NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America.  The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

 

Operating results for the six months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending September 30, 2014. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended September 30, 2013 have been omitted; this report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended September 30, 2013 included within the Company’s Form 10-K as filed with the Securities and Exchange Commission.

 

NOTE 3 - GOING CONCERN

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has recurring losses from operations and an accumulated deficit at March 31, 2014 of $27,838,150 and needs additional cash to maintain its operations.

These factors raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s continued existence is dependent upon management’s ability to develop profitable operations, continued contributions from the Company’s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company’s products and business.

 

NOTE 4 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. Significant accounting policies are as follows:

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates. The Company’s most significant estimates relate to the valuation of its proprietary technology and its valuation of its common stock.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At March 31, 2014, cash and cash equivalents include cash on hand and cash in the bank and the FDIC insures these deposits up to $250,000.

 

Impairment of Long-Lived Assets

 

Long-lived assets are evaluated for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value. The acquired software technologies are reviewed annually for impairment.

 

Fair Value of Financial Instruments

 

The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.  

 

Fair value is focused on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  Within the measurement of fair value, the use of market-based information is prioritized over entity specific information and a three-level hierarchy for fair value measurements is used based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.

The three-level hierarchy for fair value measurements is defined as follows:

 

•

Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;

•

Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;

•

Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The following table summarizes fair value measurements by level at March 31, 2014 and September 30, 2013 for assets measured at fair value on a recurring basis:

 

		Level 1				Level 2				Level 3				Total
At March 31, 2014
Software		$	—			$	—			$	701,611			$	701,611
Total Software		$	—			$	—			$	701,611			$	701,611
At September 30, 2013
Software		$	—			$	—			$	937,431			$	937,431
Total Software		$	—			$	—			$	937,431			$	937,431

 

Accounts Receivable and Allowance for Uncollectible Accounts

 

Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged against the allowance when it is probable the receivable will not be recovered. As of March 31, 2014 and 2013, the Company had no valuation allowance for the Company’s accounts receivable.

 

Income Taxes

 

The Company utilizes the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for operating loss and tax credit carry-forwards and for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that the value of such assets will be realized.

 

The Company uses the two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At March 31, 2014, the Company did not record any liabilities for uncertain tax positions.

Revenue Recognition

 

License revenue consists principally of revenue earned under software license agreements. The Company sells its software to a medical practitioner for direct payment or through a third party leasing company for direct payment to the Company. The third party lease agreement is a non-recourse debt and the Company is not responsible for the default of the medical practitioner. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (“VSOE”) exists for all undelivered elements, we account for the delivered elements in accordance with the “Residual Method.”

 

VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.

 

Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.

Subscription revenue is generated from bandwidth and information storage. In the first year and each year thereafter, the software is purchased and installed the purchaser will pay an annual fee of $1,200, $1,500, $1,800, and $2,400, respectively. Subscription revenue is recognized ratably over the term of the agreement.

 

Transaction revenue is generated from the following services and recognized when a transaction occurs:

 

·		Electronic Remittance Advise $0.35 Electronic remittance transaction fee;
·		Paper Claims $1.00 Paper claim fee;
·		Carrier Direct $0.16 Carrier direct fee;
·		Fast Forward $0.35 Fast forward transaction fee; and,
·		Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient

 

The Company had not received any transaction revenues in the three and six months ended March 31, 2014.

 

Cost of License, and Subscriptions Revenues

 

Cost of license revenue is primarily comprised of the license-based royalties to third parties and production and distribution costs for initial product licenses. No costs were incurred for license-based royalties during the three months ended March 31, 2014 and 2013.

 

Cost of subscription revenue is primarily comprised of the costs associated with the customer support personnel that provide maintenance, enhancement and support services to customers. No costs were incurred for customer support during the three months ended March 31, 2014 and 2013.

 

The amortization of acquired technology for products acquired through business combinations are considered as the cost of revenues. The acquired software technologies are amortized over their useful lives of 5 years.

Deferred Revenue

 

Deferred revenue result from fees billed to customers for which revenue has not yet been recognized or for which the conditions of the arrangement have been modified. The Company recognizes revenue to provide up-front capitalization to Cloud-MD for each provider added to the solution set. The Company also recognizes annual subscription fees for virtual servers and subscription and small usage fees and those revenues are based on a 48-month lease, Cloud-MD would amortize the revenue over the life of the agreement of 48 months. In addition, it features incremental monthly revenue, for the duration of the lease (48 months) based on fees assessed for transactions such as eligibility claims processing, etc. The Company has deferred revenue of $0 as of March 31, 2014.

 

Sales Commissions

 

The Company pays commissions, including sales bonuses, to the direct sales force related to revenue transactions under sales compensation plans which are established annually. The commission payments are typically paid in full in the month or quarter following execution of the customer contracts. The Company paid commissions of $0 and $20,000 for the three months ended March 31, 2014 and 2013, respectively, and $37,000 and $40,260 for the six months ended March 31, 2014 and 2013, respectively.

 

Research and Development and Software Development Costs

 

Capitalization of certain software development costs subsequent to the establishment of technological feasibility. Based on our product development process, technological feasibility is established upon the completion of a working model. To date, costs incurred by us from the completion of the working model to the point at which the product is ready for general release have been insignificant. Accordingly, we have charged all such costs to research and development expense in the period incurred.

 

Share-Based Compensation

 

The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period.

 

Basic and Diluted Net Income (Loss) per Common Share

 

Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding.  Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company has 4,000,000 preferred shares that can be converted subject to the limitation of the Company’s authorized shares at 1 preferred share for 150 common shares. The conversion can only take place with the approval of the Board of Directors. At March 31, 2014, the preferred shares could be converted into 600,000,000 of common shares resulting in dilution of common shareholders. The preferred shares are anti-dilutive since the losses the Company has incurred for the periods ended March 31, 2014 and 2013.

 

Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.

Concentration of Credit Risk

 

All of the Company’s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management’s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.

 

Subsequent Events

 

The Company has evaluated all transactions occurring between March 31, 2014 and through the date of issuance of the financial statements for subsequent event disclosure.

 

Recent Accounting Pronouncements

 

No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.

 

NOTE 5 – SOFTWARE

 

The following is a detail of software at March 31, 2014 and September 30, 2013:

 

		March 31, 2014				September 30, 2013
Source Code License – Antree Systems Limited		$	6,000			$	—
Encryption Software Code			15,800				15,800
Source Code License – MediSouth, LLC			2,500				2,500
Acquisition of Doctor’s Network of America			10,000				10,000
Software License			1,200,106				1,200,106
EMR Certification			23,000				23,000
Total intangible assets			1,257,406				1,251,406
Accumulated amortization of intangible assets			(545,795	)			(423,485	)
Accumulated impairment of assets			(10,000	)			(10,000	)
Total intangible assets		$	701,611			$	817,921

  

The Company’s software was placed into service starting in the second quarter of fiscal year ended September 30, 2012. The amortization expense was $61,155 and $61,155 for the three months ended March 31, 2014 and 2013, respectively. The Company recognized a $0 and $6,000 for impairment of software acquired from Doctors Network of America (“DNA”) operating in Flowood, Mississippi during the six months ended March 31, 2014 and the year ended September 30, 2013, respectively. The Company is currently in litigation with the sellers of DNA relating to the collection of certain medical billings owed to the Company. As a result of the litigation, the Company deemed the assets to be impaired.

 

Source Code License

 

In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (“URLs”) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.

Encryption Software Code

 

On November 21, 2012, the Company purchased from CipherSmith, LLC a complete source code, intellectual property rights, all computer software or algorithm licensed or sold under CipherSmith, and appropriate copy rights, patents, mask works, trademarks, service marks, internet domain names or world wide web URS. The Company issued 500,004 shares of its common stock as payment for the acquisition. The fair value of the consideration and the assets acquired is based on the aggregate fair value of the common stock issued in exchange for the software. The total fair value of the shares of common stock issued on the date of grant was $15,800.

 

Doctors Network of America

 

On June 22, 2012, the Company entered into an acquisition agreement that closed on March 16, 2013. The Company agreed to acquire DNA in Flowood, Mississippi from Krooss Medical Management Systems, LLC (“Krooss”) for 500,000 shares of common stock. As of September 30, 2012, 200,000 shares of common stock were issued as a deposit, which was valued at $4,000 based on the market value on the date of grant. At the closing of the transaction on March 16, 2013, the Company issued an additional 300,000 shares of common stock which were valued at $6,000 based on the market value on the date of grant.

 

Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts in the amount of approximately $200,000. The Company and the sellers are currently in litigation over the disputed transaction fees of $200,000.

 

NOTE 6- DISCONTINUED OPERATIONS

 

The Company’s former Board of Directors believed that it was in the best interest of the Company to discontinue the former business operation of the GPS operational device business. In 2011, this business was transferred to National Scientific, LLC, a company owned by the Company’s prior CEO, by prior management in which the Company’s former CEO was to pay $100,000 plus 2% of revenues for that technology. The former officer never paid the specific consideration for this transaction.

 

Accordingly, the Company reclassified the assets, liabilities and operations related to its GPS operational device business as discontinued operations.  Consequently, the accompanying financial statements reflect the assets, liabilities and operations of the GPS operational device business as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations.

 

On March 16, 2013, the Company closed the acquisition with the final payment for DNA. Subsequent to the transaction closing, the sellers refused to pay the transaction fees for medical billing contracts that were processed. The Company filed a lawsuit against the sellers for Breach of Contract among other things in June of 2013. During that time, the Company believes the sellers began contacting all billing contract holders and interfered with the acquisition of all the assets from the transaction. Consequently, the accompanying consolidated financial statements reflect the assets, liabilities and operations of DNA as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations.

 

Details of the classifications for net assets, liabilities and operations are shown below.

 

		March 31, 2014				September 30, 2013
Net liabilities of discontinued operations:
Accounts payable		$	42,837			$	35,356
Net liabilities of discontinued operations		$	42,837			$	35,356

		Three Months Ended March 31,
		2014				2013
Discontinued operations:
Revenues		$	53,766			$	900
Cost of sales			—				—
Operating expenses			(50,568	)			(938	)
Gain from write-off of debt			—				—
Income (loss) from discontinued operations		$	3,198			$	(38	)

 

		Six Months Ended March 31,
		2014				2013
Discontinued operations:
Revenues		$	131,050			$	900
Cost of sales			—				—
Operating expenses			(138,567	)			(938	)
Gain from write-off of debt			—				58,984
Income (loss) from discontinued operations		$	(7,517	)		$	58,946

 

NOTE 7 – LINES OF CREDIT

 

In November 2013, the Company entered into a revolving line of credit with Mutual of Omaha in the amount of $65,000 at a 4.00% interest rate per annum which renews annually. As of March 31, 2014, the Company had borrowed $62,612 against the line of credit.

 

The Company has a revolving line of credit with Chase Bank with a balance as of March 31, 2014 in the amount of $24,429 and a borrowing limit of $50,000. The line of credit with Chase Bank has an interest rate of 4.25% per annum and renews annually.

 

NOTE 8 – DEBT MITIGATION PROGRAM

 

The Company determined that the statute of limitations for certain of the Company’s creditors to enforce collection of any amounts they might be owed has now elapsed. Based on the determinations and findings, during six months ended March 31, 2014 and 2013, the Company recognized a gain on the write-off of liabilities in the amount of $0 and $58,984 from third party liabilities, respectively, which was recorded in income from discontinued operations, and additional paid-in capital of $59,704 and $0 for related party liabilities, respectively. The Company will continue to conduct this analysis going forward and write-off obligations when such obligations are no longer enforceable based on applicable law.

 

The following liabilities, through the opinion of legal counsel, were determined by the Company as unenforceable.

 

		Six Months Ended
		March  31,				March 31,
		2014				2013
Debt Mitigation Program:
Accounts payable and accrued expenses		$	59,704			$	58,984
Accrued interest			—				—
Total debt mitigation program		$	59,704			$	58,984
Gain on write-off of debt		$	—			$	(58,984	)
Additional paid-in capital (1)		$	59,704			$	—

(1)

All amounts that were owed to related parties in prior years were recorded to paid-in-capital.

NOTE 9 – COMMITMENTS AND CONTINGENCIES

 

Rent expense for the three and six months ended March 31, 2014 and 2013 was $0 for all periods.

 

The Company entered into an agreement to purchase the assets of DNA in June 2012 and after due diligence by both parties the transaction closed on March 16, 2013. Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts of approximately $200,000. In June 2013, the Company sued the sellers in federal court for breach of contract among other causes of action of unpaid medical billing transaction fees of approximately $200,000. The Company believes it will be successful in its litigation. However, if the Company is successful, the collectability of the judgment is highly questionable.

 

The Company has issued shares to new investors since January 2, 2011, that have an anti-reverse common stock split clause if the Company reverse splits the common stock. The reverse split of common stock is determined by management but must be approved by Financial Industry Regulation Authority (“FINRA”). Presently FINRA has denied the Company the right to reverse split the common stock until all Securities and Exchange Commission filings are current and at that point and time the Company will submit a request to FINRA to execute a reverse split of the common stock of the Company. The current investors holding anti-reverse split stock will have the right to hold the same number of shares of common stock as status quo after the reverse split. The anti-reverse split common stock protection is only for stock subject to reverse split and once the Company declares a reverse split and it is completed, the anti-reverse split protection will be terminate and shareholders that received anti-reverse split stock will be held with regular stockholders as the Company proceeds forward. In accordance with the anti-reverse split provision, no further shares will be issued to the anti-reverse split shareholders once the reverse split is approved and completed.

 

As discussed in Note 8, the Company has written off $59,704 and $58,984 in accounts payable, accrued liabilities and notes payable based on the opinion of legal counsel for the six months ended March 31, 2014 and 2013, respectively. However, the related creditors could make a claim in the future in regards to these liabilities.

 

NOTE 10– RELATED PARTY TRANSACTIONS

 

The Company repaid $0 and $25,591 of the advances from the Company’s CEO in the three months ended March 31, 2014 and 2013, respectively. The advances from the CEO are due on demand and do not accrue interest. As of March 31, 2014 and September 30, 2013, there were no amounts owed to the CEO for advances, respectively.

NOTE 11 - EQUITY

 

As of March 31, 2014, the Company was authorized to issue 650,000,000 common shares and 4,000,000 preferred shares at a par value of $0.01.  

 

Six Months Ended March 31, 2014

 

Stock Issued for Cash

 

During the six months ended March 31, 2014, the Company issued 35,000 shares of common stock for $15,000 in net cash proceeds as follows:

 

Date				Number of Shares				Proceeds
	October 21, 2013				25,000			$	5,000
	January 12, 2014				10,000				10,000
	Total				35,000			$	15,000

 

Stock Issued in Connection with Software Licensing and Subscription Agreements

 

During the six months ended March 31, 2014, the Company issued 220,000 shares of common stock valued at $5,700 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded as a reduction of software revenue recognized during the three months ended March 31, 2014.

 

Date				Number of Shares				Fair Value
	December 4, 2013				120,000			$	3,600
	March 4, 2014				100,000				2,100
	Total				220,000			$	5,700

 

Stock Issued for Assets Acquisition

 

In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (“URLs”) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.

 

In November 2013, the Company issued 180,000 shares of common stock as replacement shares for the 160,000 shares of common stock issued to Antree Systems Limited and 20,000 shares of common stock to Kimberly Ilicerl. The Company intends to cancel the original shares issued because the shares were lost during delivery to Antree Systems.

Stock Issued for Services

 

During the six months ended March 31, 2014, the Company issued 31,750,000 shares of common stock as compensation. The fair values of the shares were a total of $666,750 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

 

Date				Number of Shares				Fair Value				Description of Services
	March 5, 2014				31,750,000			$	666,750				Compensation
	Total				31,750,000			$	666,750

  

Six Months Ended March 31, 2013

 

Stock Issued for Cash

 

During the six months ended March 31, 2013, the Company issued 197,500 shares of common stock for $141,000 in net cash proceeds as follows:

 

Date				Number of Shares				Proceeds
	October 14, 2012				20,000			$	20,000
	October 14, 2012				15,000				3,000
	October 14, 2012				18,750				2,500
	October 14, 2012				18,750				2,500
	December 6, 2012				15,000				3,000
	March 12, 2013				20,000				20,000
	March 12, 2013				20,000				20,000
	March 31, 2013				50,000				50,000
	March 27, 2013				20,000				20,000
	Total				197,500			$	141,000

 

Stock Issued in Connection with Software Licensing and Subscription Agreements

 

During the six months ended March 31, 2013, the Company issued 300,000 shares of common stock valued at $9,350 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded as a reduction of software revenue recognized during the three months ended March 31, 2013.

 

Date				Number of Shares				Fair Value
	October 14, 2012				50,000			$	1,300
	December 6, 2012				100,000				2,800
	March 12, 2013				50,000				1,750
	March 21, 2013				50,000				1,750
	March 21, 2013				50,000				1,750
	Total				300,000			$	9,350

 

Stock Issued for Services

 

During the six months ended March 31, 2013, the Company issued 827,000 shares of common stock as compensation. The fair values of the shares were a total of $28,155 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

 

Date				Number of Shares				Fair Value				Description of Services
	October 14, 2012				10,000			$	260				Commission
	December 6, 2012				100,000				2,800				Compensation
	March 12, 2013				50,000				1,750				Consulting
	March 21, 2013				167,000				5,845				Compensation
	March 21, 2013				500,000				17,500				Compensation
	Total				827,000			$	28,155

 

Stock Issued for Assets Acquisition

 

During the six months ended March 31, 2013, the Company issued 400,000 shares of common stock for the acquisition of CipherSmith software. Those shares were valued at $13,000 based on the market price on the dates of grant.

 

Preferred Stock

 

The Company has authorized 4,000,000 shares of preferred stock, at $0.01 par value and 4,000,000 are issued and outstanding as of September 30, 2013. Each share of the Preferred Stock has 150 votes on all matters presented to be voted by the holders of our common stock. All 4,000,000 shares of preferred stock have been granted to our CEO & CFO on November 30, 2010 and issued on April 11, 2012 which was valued at the trading price of the common stock of $0.0095 and recorded as an expense of $38,000.

 

On December 17, 2013, the Company amended its Articles of Incorporation that gave the right to the holders of Preferred A shares to convert 1 share of Convertible Preferred A shares to 150 Common Shares of the Company. The holders of the Preferred A shares can convert the shares upon proper notice and approval of the Board of Directors. Presently, the holders of the Preferred A shares have not sent notice to the Board of Directors.

 

NOTE 12 – SUBSEQUENT EVENTS

 

Stock Issued for Services

 

On April 21, 2014, the Company issued 1,407,506 shares of common stock as compensation. The fair values of the shares were a total of $21,253 and were recorded at the market price on the date of grant.

In this Quarterly Report on Form 10-Q, “Company,” “our company,” “us,” and “our” refer to Cloud Medical Doctor Software Corporation and its subsidiaries, unless the context requires otherwise.

 

ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

Management’s Discussion and Analysis contains various “forward looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, regarding future events or the future financial performance of the Company that involve risks and uncertainties. Certain statements included in this Form 10-Q, including, without limitation, statements related to anticipated cash flow sources and uses, and words including but not limited to “anticipates”, “believes”, “plans”, “expects”, “future” and similar statements or expressions, identify forward looking statements. Any forward-looking statements herein are subject to certain risks and uncertainties in the Company’s business, including but not limited to, reliance on key customers and competition in its markets, market demand, delayed payments of accounts receivables, technological developments, maintenance of relationships with key suppliers, difficulties of hiring or retaining key personnel and any changes in current accounting rules, all of which may be beyond the control of the Company. Management will elect additional changes to revenue recognition to comply with the most conservative SEC recognition on a forward going accrual basis as the model is replicated with other similar markets (i.e. SBDC). The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth therein.

 

Forward-looking statements involve risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Factors and risks that could affect our results and achievements and cause them to materially differ from those contained in the forward-looking statements include those identified in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended September 30, 2013, as well as other factors that we are currently unable to identify or quantify, but that may exist in the future.

 

In addition, the foregoing factors may affect generally our business, results of operations and financial position. Forward-looking statements speak only as of the date the statement was made. We do not undertake and specifically decline any obligation to update any forward-looking statements.

 

Our Company

 

The Company was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation. During 1996, the Company acquired the operations of Eden Systems, Inc. (Eden) as a wholly owned subsidiary. Eden was engaged in water treatment and the retailing of cleaning products. Eden’s operations were sold on October 1, 1997. From September 30, 1997 through the year ended September 30, 2001, we aimed our efforts in the research and development of semiconductor proprietary technology and processes and in raising capital to fund its operations and research. Beginning in calendar 2002, we focused our efforts on the development, acquisition, enhancement and marketing of location device technologies. Our revenue was derived from sales of electronic devices, recognized as the product is delivered.

 

On February 4, 2010, the prior Board members Mr. Michael Grollman and Mr. Greg Szabo, voted to discontinue and wind down the operations of the Company's Mobile DVR and Location Products business and operate these remaining Company assets in a Limited Liability Company named NSC Labs, LLC, a company controlled and owned by Mr. Grollman. Mr. Grollman and NSC Labs, LLC entered into an agreement to pay the Company $100,000 plus 2% of revenues. As of this filing, neither Mr. Grollman nor NSC Labs, LLC have paid the specified consideration for this transaction.

 

Accordingly, the Company reclassified the assets, liabilities and operations related to its GPS operational device business as discontinued operations.  Consequently, the accompanying financial statements reflect the assets, liabilities and operations of the GPS operational device business as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations.

On November 19, 2010, the prior management was terminated and new management began working on operations related to the Company’s medical billing software. In fiscal 2011, the year of termination of prior management, new management deemed that the above transaction transferring prior operations to NSC Labs, LLC was transacted in full and final settlement of the liabilities to former management including those captioned as “disputed accrued expenses – related party” on the Balance Sheet Since the transaction was related to former management who had the ability to affect the terms and outcomes of the liabilities, the transaction has been subsequently recorded as an increase to additional paid in capital.

 

The Future for Cloud-MD™

 

Our business strategy includes the acquisition of successful billing companies in strategic markets, the acquisition or licensing of useful emerging technologies and the direct sale to physicians of Cloud-MD™ Office software licenses.

 

On the Medical Software and Billing Services side of the equation, Cloud-MD™ has already begun the sale of software licenses and the acquisition of billing companies with the purchase of Doctors Network of America, LLC and is currently in final negotiations with two others billing companies in Texas and we are currently in talks with another medical software company to acquire their software assets and customer base.

 

Our model is effective because we offer:

 

·

Software For Life – Buy One Time

·

Evergreen Product - Support, Maintenance and Upgrades Included With User License

·

Physician Ownership Opportunity – Stock Award With Purchase Of License

·

Cloud-MD™ is Publicly Traded NSCT.PK

·

Patented Auto Post Feature - To Eliminate Need For Manual Posting of Electronic Remittance Advice (835) By Staff

·

Multiple Opportunities to Recover Investment (Meaningful Use Dollars, Stock Award Option, IRS Section 179, Lower Employee and Maintenance Cost)

·

State-Of-The-Art Claims Editing and Real-Time Eligibility - Increase Collections and Reduce Days in A/R

·

Cloud Based Technology- IPAD, IPHONE, ANDROID, GOOGLE, WINDOWS for Anytime and Anywhere Availability and Eliminates Catastrophic Loss of Data

 

As we move forward building on our current platforms and strengths and gaining significant momentum in acquisitions, capabilities and revenue streams, it is important for Cloud-MD™ to augment its portfolio of capabilities with solutions that complement those offerings currently available. With the addition of a pending acquisition, we will add another dimension to our Cloud-MD™ Office and Billing Services offering that will offer a secure mechanism for providers to exchange patient PHI without the need to have all of the providers on a common EMR platform, but will integrate with our EMR in a manner that offers prospective large clients such as hospitals, ACO’s, etc. the functionality of an Electronic Health Interchange without the huge costs and overhead. In addition, we have recently developed enhanced capabilities within our Cloud-MD™ Office product offering that will offer superior solutions to hospitalists, nursing home practitioners and providers of home health services.

 

The Future for CipherLoc™

 

The digital cipher and encryption market offers seemingly endless opportunity. Our CipherLoc™ Polymorphic Cipher Engine is a ground-breaking; state-of-the-art Polymorphic Key Progression Algorithm (PKPA) based digital encryption solution that has wide-spread applicability throughout the commercial computer, communications and broadcasting industries as well as significant applicability in the government arena.

Results of Operations for the Three Months Ended March 31, 2014 and March 31, 2013

 

Revenue decreased to $105,118 from $174,214 for the three months ended March 31, 2014 and 2013, respectively. Our revenues decreased as a result of lower sales activity during the three months ended March 31, 2014 compared to the three months ended March 31, 2013. The lower sales activity is due to the Company’s focus on two potential acquisitions in Texas that deterred our focus to these potentially new opportunities.

 

Cost of revenue did not change for the three months ended March 31, 2014 and 2013, respectively. Our cost of revenue increased during the three months period due to the amortization of the software costs placed into service.

 

Selling, general and administrative expenses increased to $1,106,142 from $224,454 for the three months ended March 31, 2014 and 2013, respectively. The increase in our selling, general and administrative expenses are related to the salaries and stock-based compensation of management of $1,026,373 in the three months ended March 31, 2014 compared to $116,500 in the three months ended March 31, 2013 as well as an increase in the cost of accounting.

 

Research and development costs decreased to $30,000 from $55,000 for the three months ended March 31, 2014 and 2013, respectively. Our research and development costs decrease is related to decreased salary costs for programmers to update software required to be in compliance with the updates and modifications to the Affordable Care Act.

 

Interest expense increased to $278 from $69 for the three months ended March 31, 2014 and 2013, respectively. Our interest expense increased as a result of the increase in outstanding borrowings on our lines of credits.

 

We recorded income from discontinued operations of $3,198 compared to loss of $38 for the three months ended March 31, 2014 and 2013, respectively. The Company is currently engaged in the medical billing operations.  Until October 1, 2009, the Company’s sole sources of revenues were from GPS operational device business.  The Company discontinued its GPS operational device business in February 2010 (See “Note 6 - Discontinued Operations” to the accompanying Financial Statements).   

 

Results of Operations for the Six Months Ended March 31, 2014 and March 31, 2013

 

Revenue decreased to $222,675 from $323,571 for the six months ended March 31, 2014 and 2013, respectively. Our revenues decreased as a result of lower sales activity during the six months ended March 31, 2014 compared to the six months ended March 31, 2013. The lower sales activity is due to the Company’s focus on two potential acquisitions in Texas that deterred our focus to these potentially new opportunities.

 

Cost of revenue did not change for the six months ended March 31, 2014 and 2013, respectively. Our cost of revenue decreased during the six months period due to the amortization of the software costs placed into service.

 

Selling, general and administrative expenses increased to $1,328,218 from $343,325 for the six months ended March 31, 2014 and 2013, respectively. The increase in our selling, general and administrative expenses are related to the salaries and stock-based compensation of management of $1,026,373 in the six months ended March 31, 2014 compared to $274,264 in the six months ended March 31, 2013 as well as an increase in the cost of accounting.

 

Research and development costs decreased to $60,000 from $95,000 for the six months ended March 31, 2014 and 2013, respectively. Our research and development costs decrease is related to decreased salary costs for programmers to update software required to be in compliance with the updates and modifications to the Affordable Care Act.

 

Interest expense increased to $515 from $196 for the six months ended March 31, 2014 and 2013, respectively. Our interest expense increased as a result of the increase in outstanding borrowings on our lines of credits.

We recorded a loss from discontinued operations of $7,517 compared to income of $58,984 for the six months ended March 31, 2014 and 2013, respectively. The Company is currently engaged in the medical billing operations.  Until October 1, 2009, the Company’s sole sources of revenues were from GPS operational device business.  The Company discontinued its GPS operational device business in February 2010 (See “Note 6 - Discontinued Operations” to the accompanying Financial Statements).   

 

Liquidity and Capital Resources

 

 We expect to incur substantial expenses and generate significant operating losses as we continue to grow our operations, as well as incur expenses related to operating as a public company and compliance with regulatory requirements.

 

We have an accumulated deficit at March 31, 2014 of $27,838,150 and need additional cash flows to maintain our operations. We depend on the continued contributions of our executive officers to finance our operations and need to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of our products and business. We expect our cash needs for the next 12 months to be $850,000 to fund our operations. The ability of the Company to continue its operations is dependent on the successful execution of management’s plans, which include expectations of raiding debt or equity based capital until such time that funds from operations are sufficient to fund working capital requirements. The Company may need to incur additional liabilities with related parties to sustain the Company’s existence. There is no assurance that such funding, if required will be available to us or, if available, will be available upon terms favorable to us.

 

The Company has a revolving line of credit with Chase Bank with a balance as of March 31, 2014 in the amount of $24,429 and a borrowing limit of $50,000. We have previously received advances from our Chief Executive Officer which we have used to help fund our operations.

 

In November 2013, the Company entered into a revolving line of credit with Mutual of Omaha for a line of credit in the amount of $62,612 at 4.00% interest rate which renews annually. As of March 31, 2014, the Company had borrowed $65,000.

 

Cash flows from operations. Our cash (used in) provided by operating activities was ($93,176) and $14,205 for the six months ended March 31, 2014 and 2013, respectively. The increase in cash used in operations was primarily attributable to the increase of general and administrative expenses in 2014 as compared to the 2013 period.

 

Cash flows from financing activities. Cash provided by financing activities was $92,245 and $95,757 for the six months ended March 31, 2014 and 2013, respectively. We received cash from the sale of our common stock of $15,000 and $141,000 for the six months ended March 31, 2014 and 2013, respectively. During the six months ended March 31, 2014, received $28,245 from the Chase line of credit and received $50,000 from our Mutual of Omaha line of credit. During the six months ended March 31, 2013, we repaid the Chase line of credit of $22,152, repaid our advances from our CEO of $25,591.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements including arrangements that would affect the liquidity, capital resources, market risk support and credit risk support or other benefits.

 

WHERE YOU CAN FIND MORE INFORMATION

 

You are advised to read this Quarterly Report on Form 10-Q in conjunction with other reports and documents that we file from time to time with the SEC. In particular, please read our Quarterly Reports on Form 10-Q, Annual Report on Form 10-K, and Current Reports on Form 8-K that we file from time to time. You may obtain copies of these reports directly from us or from the SEC at the SEC’s Public Reference Room at 100 F. Street, N.E. Washington, D.C. 20549, and you may obtain information about obtaining access to the Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains information for electronic filers at its website http://www.sec.gov.

ITEM 3.         QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We do not hold any derivative instruments and do not engage in any hedging activities.

 

ITEM 4.          CONTROLS AND PROCEDURES

 

(a)

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures were designed to provide reasonable assurance that the controls and procedures would meet their objectives. As required by SEC Rule 13a-15(b), our Chief Executive Officer and Principal Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were not effective since the Company has been ineffective in filing timely.

 

Our Chief Executive Officer and Principal Financial Officer are responsible for establishing and maintaining adequate internal control over our financial reporting. In order to evaluate the effectiveness of internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act, management has conducted an assessment, including testing, using the criteria in Internal Control — Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Management has used the framework set forth in the report entitled Internal Control-Integrated Framework published by the Committee of Sponsoring Organizations of the Treadway Commission, known as COSO, to evaluate the effectiveness of our internal control over financial reporting. Based on this assessment, our Chief Executive Officer and Principal Financial Officer have concluded that our internal control over financial reporting were effective as of March 31, 2014. There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting. The Company has been ineffective in the timely filing of the company’s quarterly filings.

 

a.		There were no changes in our internal control over financial reporting that occurred during the six months ended March 31, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
b.		It should be noted that any system of controls, however well designed and operated, can provide only reasonable and not absolute assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of certain events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

PART II

OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our company’s or our company’s subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

 

On July 5, 2013, the Company filed a complaint against Krooss Medical Management Systems, LLC, William F. Krooss and Marie W. Krooss in the United States District Court, District of Nevada Case No. 2013-CV-01187-ABG-VCF for the collection of $200,000 of unpaid medical billing fees that were seriously delinquent. After many attempts by the Company to begin collections, the Defendants refused to pay the outstanding balances, however expected the Company to continue to bill for them. The Complaint includes causes of action Breach of the PTAPA, Breach of Billing and Collections Contracts, Negligence, Breach of the Duty of Good Faith and Fair Dealing, Tortious Interference with Business Relations, Fraud, among other causes of action.

 

On August 13, 2013, Krooss Medical Management Systems et al filed a Complaint in Chancery Court of Rankin County, Mississippi Case No. 13-1372 as a strategy to keep the collection matter in Mississippi Chancery Court.

 

Case No. 13-1372 was remanded to the United States District Court, Southern District of Mississippi Jackson Division Case No. 3:13CV507-HTW-LRA.

 

This litigation is a collection matter of unpaid fees by the Defendants and the Company vehemently denies the allegations (Breach of the Permanent Transfer Asset Purchase Agreement (“PTAPA”), Rescission of the PTAPA, Breach of Billing and Collections Contracts, Negligence, Quantum Meruit, Restitution, and Estoppel, Breach of the Duty of Good Faith and Fair Dealing, Tortious Interference with Business Relations, among other causes of action) filed in Mississippi Chancery Court related to this collection matter. The Company does not expect the cost to litigate this matter to adversely affect the Company’s operations. However, the Company has reduced operations in DNA-Cloud in Mississippi as the sellers have interfered with the billing contracts purchased which is one of the causes of action in Complaint, among others. Many of the contracts have been terminated due to the interference by the sellers, and DNA-Cloud has not been able to expand the business because of the reputation of the sellers in Jackson, Mississippi and the surrounding area.

 

ITEM 1A. RISK FACTORS

 

There were no material changes from the risk factors previously disclosed in Part II, Item 1A, “Risk Factors” in our  Annual Report on Form 10-K for the year ended September 30, 2013 during our six months ended March 31, 2014.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS SECURITIES

 

Period from April 1, 2014 to May 2, 2014

 

Stock Issued for Services

 

On April 21, 2014, the Company issued 1,407,506 shares of common stock as compensation. The fair values of the shares were a total of $21,253 and were recorded at the market price on the date of grant.

 

Six Months Ended March 31, 2014

 

Stock Issued for Cash

 

During the six months ended March 31, 2014, the Company issued 35,000 shares of common stock for $15,000 in net cash proceeds as follows:

 

Date				Number of Shares				Proceeds
	October 21, 2013				25,000			$	5,000
	January 12, 2014				10,000				10,000
	Total				35,000			$	15,000

 

Stock Issued in Connection with Software Licensing and Subscription Agreements

 

During the six months ended March 31, 2014, the Company issued 120,000 shares of common stock valued at $3,600 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded as a reduction of software revenue recognized during the three months ended March 31, 2014.

 

Date				Number of Shares				Fair Value
	December 4, 2013				120,000			$	3,600
	March 4, 2014				100,000				2,100
	Total				220,000			$	5,700

 

Stock Issued for Assets Acquisition

 

In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (“URLs”) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.

In November 2013, the Company issued 180,000 shares of common stock as replacement shares for the 160,000 shares of common stock issued to Antree Systems Limited and 20,000 shares of common stock to Kimberly Ilicerl. The Company intends to cancel the original shares issued because the shares were lost during delivery to Antree Systems.

 

Six Months Ended March 31, 2013

 

Stock Issued for Cash

 

During the six months ended March 31, 2013, the Company issued 197,500 shares of common stock for $141,000 in net cash proceeds as follows:

 

Date				Number of Shares				Proceeds
	October 14, 2012				20,000			$	20,000
	October 14, 2012				15,000				3,000
	October 14, 2012				18,750				2,500
	October 14, 2012				18,750				2,500
	December 6, 2012				15,000				3,000
	March 12, 2013				20,000				20,000
	March 12, 2013				20,000				20,000
	March 31, 2013				50,000				50,000
	March 27, 2013				20,000				20,000
	Total				197,500			$	141,000

 

Stock Issued in Connection with Software Licensing and Subscription Agreements

 

During the six months ended March 31, 2013, the Company issued 300,000 shares of common stock valued at $9,350 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded as a reduction of software revenue recognized during the three months ended March 31, 2013.

 

Date				Number of Shares				Fair Value
	October 14, 2012				50,000			$	1,300
	December 6, 2012				100,000				2,800
	March 12, 2013				50,000				1,750
	March 21, 2013				50,000				1,750
	March 21, 2013				50,000				1,750
	Total				300,000			$	9,350

 

Stock Issued for Services

 

During the six months ended March 31, 2013, the Company issued 827,000 shares of common stock as compensation. The fair values of the shares were a total of $28,155 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

 

Date				Number of Shares				Fair Value				Description of Services
	October 14, 2012				10,000			$	260				Commission
	December 6, 2012				100,000				2,800				Compensation
	March 12, 2013				50,000				1,750				Consulting
	March 21, 2013				167,000				5,845				Compensation
	March 21, 2013				500,000				17,500				Compensation
	Total				827,000			$	28,155

 

Stock Issued for Assets Acquisition

 

During the six months ended March 31, 2013, the Company issued 400,000 shares of common stock for the acquisition of CipherSmith software. Those shares were valued at $13,000 based on the market price on the dates of grant.

 

The offer and sale of such shares of our common stock were effected in reliance on the exemptions for sales of securities not involving a public offering, as set forth in Rule 506 promulgated under the Securities Act of 1933 (the “Securities Act”) and in Section 4(2) of the Securities Act, based on the following: (a) the investors confirmed to us that they were “accredited investors,” as defined in Rule 501 of Regulation D promulgated under the Securities Act and had such background, education and experience in financial and business matters as to be able to evaluate the merits and risks of an investment in the securities; (b) there was no public offering or general solicitation with respect to the offering; (c) the investors were provided with certain disclosure materials and all other information requested with respect to our company; (d) the investors acknowledged that all securities being purchased were “restricted securities” for purposes of the Securities Act, and agreed to transfer such securities only in a transaction registered under the Securities Act or exempt from registration under the Securities Act; and (e) a legend was placed on the certificates representing each such security stating that it was restricted and could only be transferred if subsequent registered under the Securities Act or transferred in a transaction exempt from registration under the Securities Act.

 

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

  

There were no defaults upon senior securities during the three months period ended March 31, 2014.

 

ITEM 4. MINING SAFETY DISCLOSURES 

 

N/A

  

ITEM 5.  OTHER INFORMATION

 

There is no information with respect to which information is not otherwise called for by this form.

ITEM 6.  EXHIBITS

 

Exhibits

 

3.1	Articles of Incorporation(1)
3.2	Bylaws(2)
10.1	Employment Agreement between National Scientific Corporation and Michael A. Grollman dated January 2001(4)
10.2	Employment Agreement between National Scientific Corporation and Graham L. Clark dated January 2003(6)
10.3	NSC Consulting Agreement dated August 2001, and Amendments dated August 2002 and July 2003, with Dr. El-Badawy El-Sharawy(6)
10.4	Amended and Restated 2000 Stock Option Plan(3)
10.5	Form of 2004 Stock Retainage Plan Agreement(6)
10.6	Agreement Regarding Management Consulting Services with Stanton Walker of New York dated May 2003(6)
10.7	Agreement Regarding Distribution and Marketing of Gotcha!® Child Safety Product and other products dated December 2002 with FutureCom Global, Inc. (6)
10.8	Purchase Order from Verify Systems, Inc, dated March 2003 for IBUS™ School Child Tracking Systems(5)
10.9	Letter of Understanding and Agreement dated April 2004 Regarding Sales and Distribution of Verify School safety products, and an Unlimited Software License with Anthony Grosso and CIS Services, LLC(6)
10.10	Letter of Intent from Positus, Inc. dba Bike & Cycle Trak, dated February 2003 for Design of Power Sports Tracking System(6)
10.11	Purchase Order from Positus, Inc. dba Bike & Cycle Trak, for Design of Power Sports Tracking System dated March 2003(6)
10.12	Employment agreement of Michael De La Garza(8)
10.13	Employment agreement of Pamela Thompson(8)
14	Code of Ethics(7)
31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act
31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act
32.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
32.2	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act

____________

(1)		Incorporated by reference to the Registrant’s Form 10-SB filed on or about January 3, 2000.
(2)		Incorporated by reference to the Registrant’s Form 10-QSB for the quarter ended March 31, 2001 and filed on or about May 15, 2001.
(3)		Incorporated by reference to the Registrant’s Form 10-QSB for the quarter ended December 31, 2000 and filed on or about February 14, 2001.
(4)		Incorporated by reference to the Registrant’s Form 10-KSB for the year ended September 30, 2000 and filed on or about December 19, 2000.
(5)		Incorporated by reference to the Registrant’s Form S-8 filed on or around June 3, 2003.
(6)		Incorporated by reference to the Registrant’s Form SB2 filed on or around June 24, 2004.
(7)		Incorporated by reference to the Registrant’s Form 10-QSB for the quarter ended June 30, 2004 and filed on or about August 16, 2004.
(8)		Incorporated by reference to the Registrant’s Form 10-K for the year ended September 30, 2011 and filed on or about October 10, 2013.

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Registrant   Date: May 16, 2014		Cloud Medical Doctor Software Corporation   By: /s/ Michael De La Garza
		Michael De La Garza
		Chief Executive Officer (Principal Executive Officer)

 

 

 

Registrant   Date: May 16, 2014		Cloud Medical Doctor Software Corporation   By: /s/ Pamela Thompson
		Pamela Thompson
		Principal Financial Officer